MetaCap

BioStem Technologies (BSEM) vs Passage Bio (PASG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Passage Bio (PASG) has outperformed BioStem Technologies (BSEM) over the past year, losing 49.3% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -97.3% for PASG. Passage Bio is the larger company by market cap ($12.6 million vs $12.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BSEM-83.98%PASG-49.32%
+169%+36%-96%
Nov 21, 20251 yearNov 20, 2026
BSEM-25.28%PASG-97.66%
+2716%+1242%-232%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BSEM versus PASG key metrics
MetricBSEMPASG
Share price$0.6351$3.92
Market cap$12.18M$12.61M
1-day change-10.23%+11.68%
YTD return-83.33%-66.78%
1-year return-83.98%-49.32%
5-year return-55.90%-97.30%
P/E ratio (TTM)0.72—
Forward P/E2.19—
EPS (TTM)$0.88$-10.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-45.52M
52-week high$8.40$20.00
52-week low$0.5347$3.29
Distance from 52-week high-92.44%-80.40%
Analyst consensusnonebuy
Avg. price target upside+1002.19%+295.41%
Average volume194.93K20.77K
Shares outstanding19.18M3.22M
Employees7324
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PASG has outperformed BSEM by 34.7 percentage points over the past year.

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

About Passage Bio

PASG stock →

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees

BSEM vs PASG FAQ

Which is bigger, BioStem Technologies or Passage Bio?

Passage Bio (PASG) is larger, with a market capitalization of $12.61M compared with $12.18M for BioStem Technologies (BSEM).

Which stock has performed better over the past year, BSEM or PASG?

PASG returned -49.32% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.

Are BioStem Technologies and Passage Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons